Table 5.
Univariate analysis of responders versus non-responders at 6 months based on the median of the change of night-time systolic ABP
| Baseline | ||||
|---|---|---|---|---|
| Median ≤ −13 mmHg | Median > −13 mmHg | P value | P value* | |
| Responder (n = 27) | Non-Responder (n = 26) | |||
| Change of night-time systolic BP at 6 months (mmHg) | −26.6 ± 11.1 | 3.2 ± 11.9 | <0.001 | <0.001 |
| Baseline characteristics | ||||
| BMI (kg/m2) | 30.5 ± 4.6 | 29.5 ± 3.2 | 0.338 | 0.931 |
| Gender (m/w) | 18/9 | 22/4 | 0.129 | 0.150 |
| Age (years) | 60.7 ± 10.0 | 62.4 ± 8.9 | 0.524 | 0.351 |
| Na-MRI | ||||
| Sodium in M. triceps surae (AU) | 19.8 ± 3.5 | 21.2 ± 5.3 | 0.257 | 0.251 |
| Sodium in skin (AU) | 19.7 ± 3.2 | 22.2 ± 5.1 | 0.038 | 0.016 |
| Baseline office BP | ||||
| Systolic BP (mmHg) | 157.3 ± 21.1 | 151.4 ± 19.1 | 0.290 | |
| Diastolic BP (mmHg) | 89.4 ± 13.5 | 82.3 ± 15.1 | 0.078 | |
| Heart rate(bpm) | 71.3 ± 12.8 | 67.6 ± 15.9 | 0.350 | 0.133 |
| Baseline ABP | ||||
| 24-h systolic BP (mmHg) | 160.7 ± 13.2 | 149.9 ± 14.0 | 0.005 | |
| 24-h diastolic BP (mmHg) | 90.4 ± 11.9 | 82.4 ± 10.5 | 0.011 | |
| 24-h heart rate (bpm) | 69.9 ± 11.2 | 63.6 ± 10.6 | 0.053 | 0.004 |
| Systolic day-time BP (mmHg) | 160.4 ± 13.3 | 155.0 ± 15.6 | 0.183 | |
| Diastolic day-time BP (mmHg) | 91.4 ± 11.9 | 86.7 ± 11.7 | 0.148 | |
| Heart rate day-time (bpm) | 70.6 ± 10.9 | 65.5 ± 11.3 | 0.117 | 0.017 |
| Systolic night-time BP (mmHg) | 159.9 ± 17.8 | 138.8 ± 19.1 | <0.001 | |
| Diastolic night-time BP (mmHg) | 86.6 ± 12.5 | 73.4 ± 10.7 | <0.001 | |
| Night-time heart rate (bpm) | 65.7 ± 11.6 | 58.5 ± 9.3 | 0.021 | 0.003 |
| Laboratory values | ||||
| eGFR, CKD-EPI (ml/min/1.73 m²) | 74.9 ± 25.3 | 62.8 ± 21.2 | 0.065 | 0.129 |
| Hematocrit (%) | 41.1 ± 3.5 | 40.4 ± 5.3 | 0.574 | 0.668 |
| Triglyceride | 218.8 ± 125.8 | 192.1 ± 103.0 | 0.403 | 0.291 |
| Cholesterol (mg/dl) | 201.9 ± 45.8 | 191.9 ± 57.8 | 0.487 | 0.265 |
| LDL-cholesterol (mg/dl) | 137.6 ± 34.7 | 128.2 ± 48.3 | 0.416 | 0.165 |
| Antihypertensive medication | ||||
| Diuretics, n (%) | 24 (88.9) | 25 (96.2) | 0.317 | 0.303 |
| Aldosterone-antagonist, n (%) | 5 (18.5) | 3 (11.5) | 0.478 | 0.443 |
| ACE inhibitors, n (%) | 10 (37.0) | 9 (34.6) | 0.854 | 0.720 |
| ARBs, n (%) | 21 (77.8) | 21 (80.8) | 0.788 | 0.431 |
| Direct renin inhibitors, n (%) | 13 (48.1) | 9 (34.6) | 0.318 | 0.409 |
| Betablockers, n (%) | 19 (70.4) | 23 (88.5) | 0.104 | 0.124 |
| Calcium-channel blockers, n (%) | 22 (81.5) | 23 (88.5) | 0.478 | 0.747 |
| Vasodilators, n (%) | 8 (29.6) | 11 (42.3) | 0.336 | 0.243 |
| Centrally acting sympatholytics, n (%) | 22 (81.5) | 19 (73.1) | 0.465 | 0.841 |
Data are presented as mean ± SD. Bold values represent p-values ≤ 0.05
Na sodium, Na-MRI Na magnetic resonance imaging, BP blood pressure, bpm beats per minute, ABP ambulatory blood pressure, BMI body mass index, LDL low density lipid, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
*p = adjusted for baseline 24-h night-time systolic BP